BCRX Stock Analysis: BioCryst Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 2.106m USD | 12M Return: 14.6% | US09058V1035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.3M
Qual. Beats: 0
Rev. Trend: 97.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioCryst Pharmaceuticals (NASDAQ: BCRX) is a U.S.-based biotechnology company founded in 1986 and headquartered in Durham, North Carolina. The company focuses on developing and commercializing treatments for rare diseases, with a particular emphasis on hereditary angioedema (HAE). Its commercial portfolio includes ORLADEYO, an oral serine protease inhibitor approved for HAE, and peramivir injection (marketed as RAPIVAB, RAPIACTA, and PERAMIFLU), an intravenous neuraminidase inhibitor used to treat acute, uncomplicated seasonal influenza.
The companys clinical pipeline spans multiple rare and specialty indications. Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE, is in Phase 3 development, representing the most advanced internal candidate. Earlier-stage programs include BCX17725, a KLK5-targeting protein therapeutic in Phase 1 trials for Netherton syndrome; Avoralstat, an ocular plasma kallikrein inhibitor in Phase 1 for diabetic macular edema; and STAR-0310, a monoclonal antibody OX40 antagonist in Phase 1a for atopic dermatitis. As a rare-disease-focused biotech, BioCryst operates within a regulatory environment that often supports orphan drug development through specialized pathways, and its product strategy centers on small-molecule and protein-based therapeutics targeting well-defined mechanisms such as the kallikrein-kinin system.
BioCryst maintains research and commercialization collaborations with partners including Toroi Pharmaceutical, Shionogi, Green Cross Corporation, the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), the U.S. Department of Health and Human Services, Albert Einstein College of Medicine, and Industrial Research Ltd. The company has been publicly traded since its 1994 IPO and is classified within the GICS Biotechnology sub-industry.
- ORLADEYO sales growth drives HAE franchise expansion
- Navenibart Phase 3 data readouts and approval catalyst
- Takedas Takhzyro competition pressures HAE market share
- Cash burn and path to profitability remain investor focus
| Net Income: -384.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.64 > 0.02 and ΔFCF/TA 60.57 > 1.0 |
| NWC/Revenue: 29.33% < 20% (prev 39.69%; Δ -10.37% < -1%) |
| CFO/TA 0.65 > 3% & CFO 359.9m > Net Income -384.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (265.2m) vs 12m ago 20.59% < -2% |
| Gross Margin: 23.52% > 18% (prev 97.00%; Δ -73.48% > 0.5%) |
| Asset Turnover: 185.3% > 50% (prev 121.9%; Δ 63.39% > 0%) |
| Interest Coverage Ratio: -4.10 > 6 (EBIT TTM -308.9m / Interest Expense TTM 75.3m) |
| A: 0.49 (Total Current Assets 484.7m - Total Current Liabilities 208.8m) / Total Assets 557.9m |
| B: -3.85 (Retained Earnings -2.15b / Total Assets 557.9m) |
| C: -0.61 (EBIT TTM -308.9m / Avg Total Assets 507.5m) |
| D: -0.45 (Book Value of Equity -454.3m / Total Liabilities 1.01b) |
| Altman-Z'' = -13.88 = D |
| DSRI: 0.72 (Receivables 110.8m/91.2m, Revenue 940.6m/557.5m) |
| GMI: 4.12 (GM 97.00% / 23.52%) |
| AQI: 1.09 (AQ_t 0.09 / AQ_t-1 0.08) |
| SGI: 1.69 (Revenue 940.6m / 557.5m) |
| TATA: -1.33 (NI -384.7m - CFO 359.9m) / TA 557.9m) |
| Beneish M = -0.02 (Cap -4..+1) = D |
As of October 14, 2026, the stock is trading at USD 8.07 with a total of 3,039,266 shares traded. Over the past week, the price has changed by +1.51%, over one month by -1.94%, over three months by -18.57% and over the past year by +14.63%.
Current recommended Stop Loss: 7.60 (which is 5.8% or 1.4 ATR below the current price).
BioCryst Pharmaceuticals has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy BCRX.
- StrongBuy: 7
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.7 | 156.9% |
P/E Forward = 14.4928
P/S = 2.2386
P/B = 56.5858
P/EG = 9.3878
Revenue TTM = 940.6m USD
EBIT TTM = -308.9m USD
EBITDA TTM = -303.0m USD
Long Term Debt = 778.4m USD (from longTermDebt, last quarter)
Short Term Debt = 3.00m USD (from shortTermDebt, last quarter)
Debt = 795.8m USD (corrected: LT Debt 778.4m + ST Debt 3.00m) + Leases 14.5m
Net Debt = 443.3m USD (calculated: Debt 795.8m - CCE 352.6m)
Enterprise Value = 2.55b USD (2.11b + Debt 795.8m - CCE 352.6m)
Interest Coverage Ratio = -4.10 (Ebit TTM -308.9m / Interest Expense TTM 75.3m)
EV/FCF = 7.14x (Enterprise Value 2.55b / FCF TTM 357.1m)
FCF Yield = 14.01% (FCF TTM 357.1m / Enterprise Value 2.55b)
FCF Margin = 37.97% (FCF TTM 357.1m / Revenue TTM 940.6m)
Net Margin = -40.90% (Net Income TTM -384.7m / Revenue TTM 940.6m)
Gross Margin = 23.52% ((Revenue TTM 940.6m - Cost of Revenue TTM 719.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.57 (Enterprise Value 2.55b / Total Assets 557.9m)
Interest Expense / Debt = 9.46% (Interest Expense 75.3m / Debt 795.8m)
Taxrate = 1.36% (1.08m / 79.5m)
NOPAT = -304.7m (EBIT -308.9m * (1 - 1.36%)) [loss with tax shield]
Current Ratio = 2.32 (Total Current Assets 484.7m / Total Current Liabilities 208.8m)
Debt / Equity = -1.75 (negative equity) (Debt 795.8m / totalStockholderEquity, last quarter -454.3m)
Debt / EBITDA = -1.46 (negative EBITDA) (Net Debt 443.3m / EBITDA -303.0m)
Debt / FCF = 1.24 (Net Debt 443.3m / FCF TTM 357.1m)
Total Stockholder Equity = -378.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -75.79% (Net Income -384.7m / Total Assets 557.9m)
RoE = 101.6% (negative equity) (Net Income TTM -384.7m / Total Stockholder Equity -378.8m)
RoCE = -77.31% (EBIT -308.9m / Capital Employed (Equity -378.8m + L.T.Debt 778.4m))
RoIC = -99.91% (out of range, set to none) (NOPAT -304.7m / Invested Capital 305.0m)
WACC = 8.31% (E(2.11b)/V(2.90b) * Re(7.92%) + D(795.8m)/V(2.90b) * Rd(9.46%) * (1-Tc(0.01)))
Discount Rate = 7.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.48 | Cagr: 11.86%
[DCF] Terminal Value 77.97% ; FCFF base≈220.6m ; Y1≈252.8m ; Y5≈372.1m
[DCF] Fair Price = 20.18 (EV 5.60b - Net Debt 443.3m = Equity 5.16b / Shares 255.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.44 | # QB: 0
Revenue Correlation: 97.70 | Revenue CAGR: 52.91% | SUE: 0.40 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.12 | Chg30d=+9.52% | Revisions=+40% | Analysts=2
EPS current Year (2026-12-31): EPS=0.74 | Chg30d=+12.88% | Revisions=+0% | GrowthEPS=+17.4% | GrowthRev=-18.8%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=-6.00% | Revisions=-40% | GrowthEPS=+26.2% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +0% (up=3, down=3)